26 June 2019 in Research Results in Pharmacology
Introduction: This review of literature is to demonstrate a role of group III metabotropic glutamate receptors in maintaining the level of extracellular glutamate in ischemic stroke and neurodegenerative diseases. Metabotropic glutamate receptors: mGluRs are classified into three groups. It is suggested that the activation of mGluR4 may have a neuroprotective effect. Role of excitotoxicity in the development and severity of various brain diseases: An increase in the concentration of intracellular Ca2+ is the result of excessive accumulation of glutamate in the extracellular space. And a death of nerve cells occurs after a sequence of biochemical reactions, which was called excitotoxicity. It is followed by an imbalance between glutamatergic excitation and GABA-ergic inhibition. As a result of untimely activation of the inhibitory mechanisms, the accumulation of extracellular glutamate, and consequently the death of neurons, continues, which leads to more severe manifestations of the cerebral ischemia. Role of modulation of mGluRs activity in neuroprotection: The literature describes a large number of studies proving that inhibition of hyperactive glutamatergic transmission has a neuroprotective effect. The most likely mechanisms of neuroprotection are inhibition of glutamate production in the substantia nigra, which in turn protects against glutamate-mediated excitotoxicity, and the reduction of the inflammatory effects. Anti-inflammatory effect of mGluR4 agonists in the mechanism of neuroprotective action: The astroglial component may contribute to the protective action of mGluR4 modulators, since astrocytes and microglia have mGluR4. Conclusion: mGluR4 agonists have the neuroprotective and anti-inflammatory effects.
11 June 2020 in Research Results in Pharmacology
Introduction: Tau protein is classically involved in the pathogenesis of a neurodegenerative processes, such as Parkinson’s disease. This study was aimed at testing the novel mGluR4 selective agonist using it in transgenic mice with tau-associated neurodegeneration. Materials and methods: Mice with Human P301S Tau hyperexpression were divided into 3 groups: Rapitalam 6 mg/kg and 20 mg/kg by gavage 3 times a week; and Control (Sham). The motor functions of animals were evaluated at 12th, 14th, 16th, 18th, and 20th weeks of life using the grip-test, rotarod and hanging wire test. In addition, the time of symptoms onset and death was recorded. Research results: The use of Rapitalam at a dose of 6 mg/kg and 20 mg/kg significantly restored the holding impulse on a hanging wire, increasing it from 5.06±1.25 kg×sec to 6.42±0.97 kg×sec and 8.84±1.17 kg×sec, respectively. A similar trend was observed in the grip test: Rapitalam recovered grip strength from 28.43±5.04 N in the control group to 44.27±5.54 N (6 mg/kg) and 59.53±7.95 (20 mg/kg). Finally, the two-month use of Rapitalam neither delayed the manifestation of symptoms, nor increased the survival of mice. Discussion: The cause of the loss of nerve cells in the mouse-tau line is autophagy. Apparently, Rapitalam is not able to simulate this process by reducing excitotoxicity, but against the background of the neurodegenerative process, it increases the activity of the nerve cells. Conclusion: Rapitalam improves motor dysfunction in mice with tauopathy, with no effect on the survival of animals.
1 January 2018 in University proceedings. Volga region. Medical sciences
BUBelgorod State National Research University
Belgorod State National Research University
+2
Статья 18318. Пензенский государственный университет
30 March 2020 in Research Results in Pharmacology
Introduction: The virtual target-oriented screening is a necessary stage of modern drug-design. In the present study, the affinity of pyridazine derivatives for the most promising antiparkinsonian biotargets – I–III groups of metabotropic and ionotropic NMDA-glutamate receptors – was evaluated. Materials and methods: Docking of the studied ligands to the active sites of biotargets – mGluR5, mGluR3, mGluR8, NMDA GluN2B – was performed using AutoDockVina. Base of the preparation of ligands and proteins – AutoDockTools-1.5.6. A Discovery Studio Visualizer 2017/R2 was used to visualize the interpretation of the results. Results and discussion: A high degree of the affinity is predicted for group III of the metabotropic mGlu8 receptors – binding energy from -5.0 to -8.7 kcal/mol, compared to -6.1 kcal/mol of that of the reference drug (L-AP4), as well as for the ionotropic NMDA GluN2B receptors –binding energy from -8.7 to -11.6 kcal/mol, compared to -11.3 kcal/mol of that of ifenprodil. Conclusion: The prospects of the searching for glutamate receptor modulators in a number of n-substituted 4-methoxy-6-oxo-1-aryl-pyridazine-3-carboxamide derivatives are proved. Some aspects of the structure-affinity relationship are discussed.
11 May 2019 in Pharmacy & Pharmacology
Parkinson’s disease is the second most common (after Alzheimer’s) neurodegenerative disease. All over the world, there is a search for new drugs aimed at the treatment of Parkinson’s disease. Till up to the present, there is no “ideal” medicine that can completely cure this disease and has minimal adverse side effects. Belgorod research institute of pharmacology of living systems is studying Rapitalam, a new drug for the treatment of tremulous Parkinson’s disease. This is an agonist of the mGluR4 group of metabotropic receptors.The aim of the article is to study Rapitalam influence on the oxotremorine-induced tremor in rats.Methods. The study comprised 60 rats (6 groups of 10 males), which were administered intragastrically with the studied substances for 10 days. All the animal groups except Control group 1, were administered with Rapitalam and the reference drug Levodopa. 30 minutes after Rapitalam and Levodopa, they were administered abdominally with the solution of Oxotremorine at the dose of 1.5 mg/kg. The animals of Control group 1, instead of Oxotremorine, were similarly administered with a solvent of 0.9% sodium chloride in the equivalent volume.Results. In comparison with the reference group, Rapitalam at the dose of 3 mg/kg significantly reduced the severity of tremor 50 min. after its administration. The same effect took place 30 min after the administration of Oxotremorine at the dose of 10 mg/kg. At the dose of 3 and 10 mg/kg, Rapitalam also decreased the number of rats in the group (in %) with the signs of tremor 60 min. and 50 min. after the administration of Oxotremorine, respectively.Conclusion. The study revealed that Rapitalam has a pronounced anti-tremor effect. Its administration at the studied doses reduced the symptoms of Oxotremorine-induced tremor in rats.